Medicamentos esenciales y Acuerdo sobre los ADPIC: Colisión entre el derecho a la salud y el derecho de propiedad intelectual

6Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

The strengthening of pharmaceutical patent protection globally puts strains on access to essential medicines. According to the present paper, this process has led to the collision of the intellectual property rights adopted in the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and the right to health stated in the International Covenant on Economic, Social and Cultural Rights (ICE SCR). Several controversies disputed in the WTO illustrate the confrontation between countries with a powerful pharmaceutical industry and the interests of developing countries. It is concluded that the TRIPS-plus rules subscribed to by developing countries in free trade agreements which give the pharmaceutical patent holder more rights than those stipulated in the original TRIPS Agreement are incompatible with the obligations to provide access to essential medicines under the right to health of the ICESCR.

Cite

CITATION STYLE

APA

Allard Soto, R. (2015). Medicamentos esenciales y Acuerdo sobre los ADPIC: Colisión entre el derecho a la salud y el derecho de propiedad intelectual. Salud Colectiva, 11(1), 9–21. https://doi.org/10.18294/sc.2015.412

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free